German smartbax closes seed financing of €1.2M for 'new solutions against multi-drug resistant pathogens'
A biotech advancing small molecule antibiotics through preclinical studies has closed its seed financing round of €1.2million ($1.3million) from Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF).